| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
19,729 |
18,296 |
$2.37M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
16,795 |
15,801 |
$2.19M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,026 |
4,563 |
$614K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
6,453 |
5,274 |
$412K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
6,052 |
5,736 |
$390K |
| 80053 |
Comprehensive metabolic panel |
20,673 |
18,768 |
$332K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,271 |
1,192 |
$315K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,879 |
2,730 |
$286K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
4,192 |
4,028 |
$230K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
7,073 |
6,595 |
$203K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
4,177 |
4,015 |
$160K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
7,071 |
5,861 |
$141K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
26,974 |
24,720 |
$76K |
| 87081 |
|
3,376 |
3,063 |
$68K |
| 87631 |
|
1,010 |
927 |
$67K |
| 87653 |
|
1,094 |
1,049 |
$65K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,323 |
1,252 |
$35K |
| 87510 |
|
655 |
624 |
$28K |
| 87077 |
|
1,895 |
1,800 |
$24K |
| 87480 |
|
655 |
624 |
$18K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
306 |
280 |
$18K |
| 87632 |
|
252 |
214 |
$16K |
| 80320 |
|
304 |
248 |
$16K |
| 87505 |
|
244 |
234 |
$15K |
| 87660 |
|
655 |
624 |
$14K |
| 87070 |
|
490 |
459 |
$12K |
| 87186 |
|
1,998 |
1,885 |
$10K |
| J3490 |
Unclassified drugs |
6,019 |
4,835 |
$8K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
40 |
38 |
$8K |
| 87147 |
|
1,002 |
959 |
$6K |
| 81001 |
|
2,995 |
2,790 |
$5K |
| 84484 |
|
459 |
381 |
$4K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
14 |
14 |
$4K |
| 87088 |
|
445 |
433 |
$4K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
9,527 |
8,864 |
$4K |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
53 |
53 |
$3K |
| 87177 |
|
85 |
81 |
$3K |
| 86769 |
|
62 |
62 |
$3K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
57 |
57 |
$2K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
54 |
51 |
$2K |
| 87209 |
|
85 |
81 |
$2K |
| 87205 |
|
240 |
226 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
524 |
456 |
$2K |
| 87506 |
|
15 |
14 |
$1K |
| 83605 |
|
46 |
41 |
$1K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,808 |
2,492 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
150 |
141 |
$1K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
5,640 |
5,174 |
$1K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
13 |
13 |
$1K |
| 81003 |
|
751 |
693 |
$959.44 |
| 87449 |
|
53 |
50 |
$958.09 |
| 84439 |
|
133 |
128 |
$923.19 |
| 80061 |
Lipid panel |
126 |
125 |
$688.68 |
| 36415 |
Collection of venous blood by venipuncture |
128 |
116 |
$574.72 |
| 87075 |
|
12 |
12 |
$536.98 |
| 71045 |
Radiologic examination, chest; single view |
1,209 |
1,128 |
$452.83 |
| 83735 |
|
383 |
344 |
$418.07 |
| 87324 |
|
53 |
50 |
$417.77 |
| 86140 |
|
35 |
23 |
$343.06 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,514 |
2,333 |
$265.03 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
5,322 |
4,956 |
$261.68 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
16,241 |
12,577 |
$200.51 |
| 84702 |
|
18 |
14 |
$170.24 |
| 85027 |
|
1,497 |
1,373 |
$138.67 |
| 84466 |
|
12 |
12 |
$105.84 |
| 83690 |
|
2,667 |
2,488 |
$102.51 |
| 87328 |
|
15 |
14 |
$90.48 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,183 |
2,050 |
$88.51 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
446 |
418 |
$65.80 |
| 83540 |
|
14 |
14 |
$48.48 |
| 80306 |
|
509 |
422 |
$29.57 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
140 |
136 |
$24.79 |
| 84703 |
|
528 |
498 |
$22.71 |
| 85610 |
|
309 |
248 |
$5.56 |
| 87329 |
|
15 |
14 |
$3.48 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
502 |
469 |
$2.56 |
| 81025 |
|
399 |
373 |
$0.00 |
| 71046 |
Radiologic examination, chest; 2 views |
183 |
169 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
177 |
162 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
138 |
110 |
$0.00 |
| 84100 |
|
13 |
13 |
$0.00 |
| S0028 |
Injection, famotidine, 20 mg |
14 |
12 |
$0.00 |
| 82947 |
|
22 |
12 |
$0.00 |
| 36416 |
|
260 |
203 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
142 |
95 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
167 |
152 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
183 |
154 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
31 |
12 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
18 |
12 |
$0.00 |
| A9270 |
Non-covered item or service |
31 |
12 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
13 |
13 |
$0.00 |